by barry101 | Aug 16, 2024 | Press Releases
$5.5 million financing upfront with up to an additional $11.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HOUSTON, Aug. 16, 2024 /PRNewswire-PRWeb/ — Moleculin Biotech, Inc., (Nasdaq: MBRX)...
by barry101 | Aug 14, 2024 | Press Releases
– Positive outcome from End of Phase 1B/2 Meeting with FDA – Company proceeding with a pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the...
by barry101 | Aug 5, 2024 | Press Releases
HOUSTON, Aug. 5, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today...
by barry101 | Aug 1, 2024 | Press Releases
Based on an encouraging discussion in the End of Phase 1B/2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) designed for possible accelerated approval of Annamycin in combination with...
by barry101 | Jul 10, 2024 | Press Releases
HOUSTON, July 10, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced...
by barry101 | Jun 14, 2024 | Press Releases
– 89% of CRc’s were subjects with “poor prognosis” cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc’s = 6 months and increasing (n=9) – In 2nd line subjects (n=10) Annamycin in combination...
